 Jill Slansky
Concepts (305)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cancer Vaccines | 13 | 2021 | 139 | 3.140 |
Why?
| | Receptors, Antigen, T-Cell | 14 | 2023 | 632 | 2.840 |
Why?
| | CD8-Positive T-Lymphocytes | 18 | 2023 | 702 | 2.770 |
Why?
| | Antigens, Neoplasm | 12 | 2023 | 228 | 2.360 |
Why?
| | Neoplasms | 12 | 2023 | 2179 | 2.290 |
Why?
| | T-Lymphocytes | 13 | 2023 | 1774 | 2.190 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 5 | 2023 | 112 | 2.060 |
Why?
| | Vaccines, Subunit | 4 | 2013 | 42 | 1.310 |
Why?
| | Peptides | 8 | 2023 | 879 | 1.100 |
Why?
| | T-Lymphocytes, Cytotoxic | 6 | 2022 | 158 | 1.030 |
Why?
| | Epitopes, T-Lymphocyte | 6 | 2012 | 170 | 1.030 |
Why?
| | Immunotherapy | 7 | 2021 | 493 | 0.840 |
Why?
| | Granzymes | 1 | 2022 | 40 | 0.830 |
Why?
| | Mice, Inbred BALB C | 16 | 2021 | 1206 | 0.820 |
Why?
| | Lymphocyte Activation | 11 | 2019 | 1067 | 0.790 |
Why?
| | Tumor Escape | 3 | 2019 | 38 | 0.780 |
Why?
| | Baculoviridae | 3 | 2009 | 46 | 0.730 |
Why?
| | Antigen Presentation | 6 | 2018 | 194 | 0.730 |
Why?
| | Neoplasms, Experimental | 2 | 2021 | 158 | 0.720 |
Why?
| | Immunomodulation | 1 | 2020 | 89 | 0.690 |
Why?
| | Immunogenetic Phenomena | 1 | 2019 | 6 | 0.690 |
Why?
| | Peptide Library | 4 | 2013 | 80 | 0.690 |
Why?
| | Epitopes | 2 | 2020 | 443 | 0.660 |
Why?
| | Insecta | 3 | 2009 | 68 | 0.660 |
Why?
| | Histocompatibility Antigens Class I | 6 | 2019 | 177 | 0.650 |
Why?
| | Major Histocompatibility Complex | 4 | 2008 | 220 | 0.630 |
Why?
| | Alternative Splicing | 1 | 2019 | 193 | 0.610 |
Why?
| | Animals | 43 | 2023 | 33381 | 0.580 |
Why?
| | H-2 Antigens | 4 | 2008 | 111 | 0.570 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2019 | 1167 | 0.560 |
Why?
| | Colorectal Neoplasms | 5 | 2019 | 628 | 0.530 |
Why?
| | Autoimmunity | 2 | 2020 | 831 | 0.530 |
Why?
| | Tumor Microenvironment | 5 | 2023 | 454 | 0.530 |
Why?
| | Mice | 30 | 2023 | 15520 | 0.530 |
Why?
| | Neoplasm Proteins | 2 | 2018 | 401 | 0.500 |
Why?
| | Vaccines | 2 | 2010 | 380 | 0.500 |
Why?
| | Antigens | 3 | 2019 | 320 | 0.500 |
Why?
| | Up-Regulation | 3 | 2019 | 872 | 0.480 |
Why?
| | CD4-Positive T-Lymphocytes | 3 | 2019 | 984 | 0.450 |
Why?
| | Colonic Neoplasms | 3 | 2012 | 224 | 0.450 |
Why?
| | B-Lymphocytes | 1 | 2017 | 770 | 0.430 |
Why?
| | Complementarity Determining Regions | 1 | 2012 | 45 | 0.420 |
Why?
| | Allergy and Immunology | 1 | 2013 | 57 | 0.420 |
Why?
| | Antigenic Variation | 1 | 2011 | 9 | 0.420 |
Why?
| | Moloney murine leukemia virus | 1 | 2011 | 11 | 0.410 |
Why?
| | Viral Envelope Proteins | 1 | 2011 | 80 | 0.390 |
Why?
| | Breast Neoplasms | 3 | 2018 | 1965 | 0.390 |
Why?
| | Cell Cycle Proteins | 6 | 1997 | 565 | 0.360 |
Why?
| | Carrier Proteins | 6 | 1997 | 726 | 0.360 |
Why?
| | Histocompatibility Antigens | 2 | 2020 | 102 | 0.350 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 968 | 0.340 |
Why?
| | DNA-Binding Proteins | 8 | 2018 | 1346 | 0.340 |
Why?
| | Autoimmune Diseases | 1 | 2012 | 398 | 0.330 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 2 | 2022 | 310 | 0.330 |
Why?
| | Liver Neoplasms | 4 | 2020 | 527 | 0.320 |
Why?
| | Tetrahydrofolate Dehydrogenase | 4 | 1997 | 14 | 0.320 |
Why?
| | Mice, Transgenic | 5 | 2023 | 2025 | 0.310 |
Why?
| | Inflammation | 4 | 2020 | 2566 | 0.310 |
Why?
| | Cross Reactions | 2 | 2020 | 116 | 0.290 |
Why?
| | Vaccination | 3 | 2010 | 1222 | 0.290 |
Why?
| | Triple Negative Breast Neoplasms | 2 | 2019 | 164 | 0.280 |
Why?
| | Lung Neoplasms | 2 | 2017 | 2220 | 0.280 |
Why?
| | Immune Tolerance | 1 | 2008 | 334 | 0.270 |
Why?
| | Flow Cytometry | 6 | 2016 | 1085 | 0.260 |
Why?
| | Disease Models, Animal | 3 | 2021 | 3730 | 0.260 |
Why?
| | Histocompatibility Antigens Class II | 2 | 2003 | 355 | 0.250 |
Why?
| | Humans | 34 | 2022 | 118972 | 0.250 |
Why?
| | Graft Rejection | 2 | 2007 | 555 | 0.250 |
Why?
| | Cytotoxicity, Immunologic | 4 | 2012 | 204 | 0.230 |
Why?
| | Listeria monocytogenes | 3 | 2011 | 110 | 0.230 |
Why?
| | Lymphocyte Count | 4 | 2017 | 136 | 0.230 |
Why?
| | Cell Line, Tumor | 9 | 2021 | 2851 | 0.230 |
Why?
| | Models, Biological | 1 | 2010 | 1715 | 0.220 |
Why?
| | Amino Acid Substitution | 2 | 2020 | 276 | 0.220 |
Why?
| | Transcription Factors | 6 | 1997 | 1570 | 0.220 |
Why?
| | Female | 22 | 2021 | 61564 | 0.210 |
Why?
| | Aging | 2 | 2011 | 1670 | 0.210 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 1390 | 0.200 |
Why?
| | Dendritic Cells | 3 | 2014 | 442 | 0.200 |
Why?
| | Histocompatibility Antigen H-2D | 4 | 2022 | 21 | 0.200 |
Why?
| | Base Sequence | 7 | 2016 | 2159 | 0.200 |
Why?
| | Receptor-CD3 Complex, Antigen, T-Cell | 1 | 2000 | 7 | 0.190 |
Why?
| | Heterografts | 1 | 2021 | 130 | 0.190 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2020 | 40 | 0.190 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2019 | 197 | 0.180 |
Why?
| | Immune System | 1 | 2021 | 181 | 0.180 |
Why?
| | Gene Editing | 1 | 2020 | 63 | 0.180 |
Why?
| | Chemokines, CXC | 1 | 2019 | 64 | 0.180 |
Why?
| | CRISPR-Cas Systems | 1 | 2020 | 85 | 0.170 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2020 | 360 | 0.170 |
Why?
| | Bcl-2-Like Protein 11 | 1 | 2019 | 38 | 0.170 |
Why?
| | Gene Transfer Techniques | 1 | 2020 | 154 | 0.170 |
Why?
| | Nanotechnology | 1 | 2020 | 120 | 0.170 |
Why?
| | Interleukin-12 | 1 | 2019 | 110 | 0.170 |
Why?
| | Tryptophan Oxygenase | 1 | 2018 | 22 | 0.170 |
Why?
| | Calcineurin | 1 | 2019 | 95 | 0.170 |
Why?
| | Mutation | 5 | 2020 | 3457 | 0.170 |
Why?
| | Mice, Knockout | 4 | 2021 | 2680 | 0.170 |
Why?
| | Oligopeptides | 1 | 2000 | 252 | 0.170 |
Why?
| | Autoantigens | 1 | 2021 | 397 | 0.160 |
Why?
| | Genetic Therapy | 1 | 2020 | 267 | 0.160 |
Why?
| | Neoadjuvant Therapy | 1 | 2020 | 333 | 0.160 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 65 | 0.160 |
Why?
| | Disease Susceptibility | 1 | 2020 | 331 | 0.160 |
Why?
| | Promoter Regions, Genetic | 5 | 1997 | 1158 | 0.160 |
Why?
| | Cell Line | 2 | 2016 | 2707 | 0.150 |
Why?
| | Tryptophan | 1 | 2018 | 139 | 0.150 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2018 | 145 | 0.150 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2019 | 200 | 0.150 |
Why?
| | Immunodominant Epitopes | 2 | 2010 | 27 | 0.150 |
Why?
| | Antigen-Presenting Cells | 1 | 2017 | 156 | 0.150 |
Why?
| | Sarcoidosis, Pulmonary | 1 | 2017 | 56 | 0.150 |
Why?
| | Genetic Engineering | 2 | 2009 | 83 | 0.150 |
Why?
| | Transcriptional Activation | 2 | 2018 | 348 | 0.150 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 156 | 0.150 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2017 | 453 | 0.140 |
Why?
| | Immunophenotyping | 1 | 2017 | 278 | 0.140 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 144 | 0.140 |
Why?
| | Spodoptera | 2 | 2021 | 37 | 0.140 |
Why?
| | Ligands | 4 | 2018 | 567 | 0.140 |
Why?
| | Mononuclear Phagocyte System | 1 | 2016 | 14 | 0.140 |
Why?
| | Emulsions | 1 | 2016 | 45 | 0.140 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2016 | 770 | 0.140 |
Why?
| | Papillomavirus Infections | 1 | 2019 | 265 | 0.140 |
Why?
| | Lymph Nodes | 2 | 2016 | 455 | 0.140 |
Why?
| | Phagocytes | 1 | 2016 | 91 | 0.130 |
Why?
| | Ovarian Neoplasms | 1 | 2020 | 420 | 0.130 |
Why?
| | Lung | 3 | 2017 | 3664 | 0.130 |
Why?
| | Gene Expression Regulation | 4 | 2022 | 2445 | 0.130 |
Why?
| | Cell Separation | 1 | 2016 | 296 | 0.130 |
Why?
| | T-Lymphocyte Subsets | 4 | 2007 | 396 | 0.130 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2017 | 613 | 0.130 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 1993 | 290 | 0.130 |
Why?
| | Polymerase Chain Reaction | 2 | 2016 | 1012 | 0.120 |
Why?
| | Retinoblastoma-Binding Protein 1 | 6 | 1997 | 22 | 0.120 |
Why?
| | Interferon-gamma | 5 | 2011 | 736 | 0.120 |
Why?
| | E2F Transcription Factors | 6 | 1997 | 55 | 0.120 |
Why?
| | Head and Neck Neoplasms | 1 | 2019 | 471 | 0.120 |
Why?
| | Transcription Factor DP1 | 5 | 1997 | 21 | 0.120 |
Why?
| | Prognosis | 2 | 2020 | 3443 | 0.110 |
Why?
| | Colorado | 2 | 2013 | 4196 | 0.110 |
Why?
| | Gene Expression Profiling | 2 | 2010 | 1597 | 0.110 |
Why?
| | T-Lymphocytes, Regulatory | 3 | 2012 | 359 | 0.100 |
Why?
| | Molecular Sequence Data | 8 | 2006 | 2871 | 0.100 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 827 | 0.100 |
Why?
| | Transcription, Genetic | 3 | 1997 | 1323 | 0.100 |
Why?
| | Lymphoma, B-Cell | 1 | 2012 | 85 | 0.100 |
Why?
| | Hemangiosarcoma | 1 | 2010 | 19 | 0.100 |
Why?
| | Universities | 1 | 2013 | 347 | 0.090 |
Why?
| | Mice, Inbred C57BL | 5 | 2019 | 4908 | 0.090 |
Why?
| | Carcinoma | 1 | 2011 | 204 | 0.090 |
Why?
| | Research | 1 | 2013 | 411 | 0.090 |
Why?
| | Genes, MHC Class I | 1 | 2009 | 33 | 0.090 |
Why?
| | Down-Regulation | 1 | 2011 | 627 | 0.080 |
Why?
| | Neovascularization, Pathologic | 1 | 2010 | 287 | 0.080 |
Why?
| | Cross-Priming | 1 | 2008 | 20 | 0.080 |
Why?
| | E2F1 Transcription Factor | 4 | 1997 | 56 | 0.080 |
Why?
| | CD11c Antigen | 1 | 2008 | 38 | 0.080 |
Why?
| | Adjuvants, Immunologic | 1 | 2009 | 207 | 0.080 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2021 | 740 | 0.080 |
Why?
| | Protein Conformation | 2 | 2003 | 848 | 0.080 |
Why?
| | Biomarkers | 1 | 2017 | 3588 | 0.070 |
Why?
| | Cell Culture Techniques | 1 | 2009 | 356 | 0.070 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2006 | 59 | 0.070 |
Why?
| | RNA, Messenger | 2 | 1994 | 2657 | 0.070 |
Why?
| | Aged, 80 and over | 1 | 2017 | 6561 | 0.070 |
Why?
| | Male | 8 | 2020 | 57801 | 0.070 |
Why?
| | Drug Design | 1 | 2006 | 160 | 0.070 |
Why?
| | DNA Primers | 1 | 2006 | 533 | 0.070 |
Why?
| | Melanoma, Experimental | 1 | 2006 | 118 | 0.060 |
Why?
| | S Phase | 2 | 1996 | 74 | 0.060 |
Why?
| | Amino Acid Sequence | 5 | 2018 | 2071 | 0.060 |
Why?
| | G1 Phase | 2 | 1996 | 68 | 0.060 |
Why?
| | Antigens, Surface | 2 | 2001 | 156 | 0.060 |
Why?
| | Clone Cells | 2 | 2003 | 248 | 0.060 |
Why?
| | Liver Neoplasms, Experimental | 1 | 2003 | 25 | 0.060 |
Why?
| | 3T3 Cells | 4 | 2003 | 141 | 0.060 |
Why?
| | Cells, Cultured | 1 | 2011 | 4077 | 0.060 |
Why?
| | Genes, erbB-2 | 1 | 2003 | 27 | 0.060 |
Why?
| | Middle Aged | 3 | 2020 | 27617 | 0.060 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2003 | 63 | 0.060 |
Why?
| | Germ Cells | 1 | 2022 | 64 | 0.050 |
Why?
| | Aged | 2 | 2017 | 19657 | 0.050 |
Why?
| | Molecular Conformation | 1 | 2022 | 146 | 0.050 |
Why?
| | Interleukin-2 | 1 | 2003 | 416 | 0.050 |
Why?
| | Transglutaminases | 1 | 2022 | 143 | 0.050 |
Why?
| | Sf9 Cells | 1 | 2021 | 9 | 0.050 |
Why?
| | Chimerism | 1 | 2021 | 28 | 0.050 |
Why?
| | B7-1 Antigen | 1 | 2001 | 69 | 0.050 |
Why?
| | Lymphoid Tissue | 1 | 2021 | 65 | 0.050 |
Why?
| | Lymphocyte Subsets | 1 | 2021 | 76 | 0.050 |
Why?
| | Immunoglobulins | 1 | 2001 | 154 | 0.050 |
Why?
| | Alanine | 1 | 2000 | 102 | 0.050 |
Why?
| | Surface Plasmon Resonance | 1 | 2000 | 85 | 0.050 |
Why?
| | Mice, SCID | 1 | 2021 | 333 | 0.050 |
Why?
| | Dogs | 2 | 2012 | 371 | 0.050 |
Why?
| | Recombinant Proteins | 1 | 2003 | 1308 | 0.050 |
Why?
| | Cyclophosphamide | 2 | 2011 | 222 | 0.040 |
Why?
| | Mice, Inbred NOD | 1 | 2021 | 574 | 0.040 |
Why?
| | Skin Neoplasms | 1 | 2006 | 762 | 0.040 |
Why?
| | Paraparesis, Tropical Spastic | 1 | 1998 | 1 | 0.040 |
Why?
| | Gene Products, tax | 1 | 1998 | 9 | 0.040 |
Why?
| | Models, Molecular | 1 | 2003 | 1435 | 0.040 |
Why?
| | Lymphocytic Choriomeningitis | 1 | 1998 | 12 | 0.040 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 311 | 0.040 |
Why?
| | Kynurenine | 1 | 2018 | 81 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor, Member 25 | 1 | 2017 | 3 | 0.040 |
Why?
| | Drug Delivery Systems | 1 | 2020 | 306 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1166 | 0.040 |
Why?
| | HLA-DRB1 Chains | 1 | 2017 | 97 | 0.040 |
Why?
| | Mice, Nude | 1 | 2019 | 663 | 0.040 |
Why?
| | Antigens, Viral | 1 | 1998 | 181 | 0.040 |
Why?
| | Antigens, CD | 2 | 2014 | 460 | 0.040 |
Why?
| | HLA Antigens | 1 | 2018 | 230 | 0.040 |
Why?
| | High-Throughput Screening Assays | 1 | 2018 | 122 | 0.040 |
Why?
| | Folic Acid Antagonists | 1 | 1996 | 8 | 0.030 |
Why?
| | Survival Rate | 1 | 2020 | 1720 | 0.030 |
Why?
| | Sp1 Transcription Factor | 1 | 1996 | 23 | 0.030 |
Why?
| | Enzyme Induction | 1 | 1996 | 94 | 0.030 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 1996 | 80 | 0.030 |
Why?
| | Gene Amplification | 1 | 1996 | 97 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2021 | 540 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 969 | 0.030 |
Why?
| | Cadaver | 1 | 2016 | 327 | 0.030 |
Why?
| | Integrin alpha Chains | 1 | 2014 | 22 | 0.030 |
Why?
| | Interleukin-27 | 1 | 2014 | 12 | 0.030 |
Why?
| | Toll-Like Receptor 3 | 1 | 2014 | 31 | 0.030 |
Why?
| | Poly I-C | 1 | 2014 | 55 | 0.030 |
Why?
| | Toll-Like Receptor 7 | 1 | 2014 | 35 | 0.030 |
Why?
| | Acute Disease | 1 | 2017 | 940 | 0.030 |
Why?
| | CD11b Antigen | 1 | 2014 | 59 | 0.030 |
Why?
| | DNA Replication | 1 | 1996 | 211 | 0.030 |
Why?
| | DNA | 3 | 1997 | 1388 | 0.030 |
Why?
| | Cell Division | 2 | 1993 | 776 | 0.030 |
Why?
| | Cell Cycle | 2 | 1994 | 550 | 0.030 |
Why?
| | Culture Media, Serum-Free | 1 | 1993 | 42 | 0.030 |
Why?
| | Imidazoles | 1 | 2014 | 232 | 0.030 |
Why?
| | Serum Response Factor | 1 | 1993 | 31 | 0.030 |
Why?
| | RNA Polymerase II | 1 | 1996 | 282 | 0.030 |
Why?
| | Phenotype | 1 | 2021 | 3003 | 0.030 |
Why?
| | Cloning, Molecular | 3 | 2001 | 546 | 0.030 |
Why?
| | Antineoplastic Agents | 1 | 2003 | 1974 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 2014 | 446 | 0.030 |
Why?
| | Disease Progression | 1 | 2019 | 2490 | 0.030 |
Why?
| | Proteomics | 1 | 2018 | 876 | 0.030 |
Why?
| | Antigens, Differentiation | 1 | 2011 | 79 | 0.030 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 2011 | 69 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2020 | 4596 | 0.030 |
Why?
| | CTLA-4 Antigen | 1 | 2011 | 86 | 0.020 |
Why?
| | Cytokines | 1 | 2019 | 1900 | 0.020 |
Why?
| | Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2010 | 11 | 0.020 |
Why?
| | Protein Biosynthesis | 1 | 1993 | 397 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2011 | 403 | 0.020 |
Why?
| | Doxorubicin | 1 | 2012 | 302 | 0.020 |
Why?
| | ras Proteins | 1 | 2010 | 141 | 0.020 |
Why?
| | Nuclear Proteins | 1 | 1993 | 597 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2011 | 1293 | 0.020 |
Why?
| | Protein Binding | 2 | 2006 | 1975 | 0.020 |
Why?
| | Survival Analysis | 1 | 2011 | 1267 | 0.020 |
Why?
| | DNA, Complementary | 2 | 2001 | 268 | 0.020 |
Why?
| | Vaccines, Attenuated | 1 | 2007 | 114 | 0.020 |
Why?
| | Binding Sites | 3 | 1997 | 1224 | 0.020 |
Why?
| | Injections, Intradermal | 1 | 2006 | 11 | 0.020 |
Why?
| | Peptide Fragments | 2 | 2003 | 702 | 0.020 |
Why?
| | Enterotoxins | 1 | 2006 | 86 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2006 | 245 | 0.020 |
Why?
| | Hepatitis | 1 | 2006 | 46 | 0.020 |
Why?
| | Adult | 2 | 2017 | 31512 | 0.020 |
Why?
| | Cell Adhesion | 1 | 2006 | 443 | 0.020 |
Why?
| | Killer Cells, Natural | 1 | 2007 | 381 | 0.020 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2003 | 49 | 0.010 |
Why?
| | Growth Inhibitors | 1 | 2003 | 43 | 0.010 |
Why?
| | Vaccines, DNA | 1 | 2003 | 32 | 0.010 |
Why?
| | Peptide Mapping | 1 | 2003 | 63 | 0.010 |
Why?
| | Cell Line, Transformed | 1 | 2003 | 136 | 0.010 |
Why?
| | Injections, Intravenous | 1 | 2003 | 210 | 0.010 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2003 | 143 | 0.010 |
Why?
| | Adoptive Transfer | 1 | 2003 | 204 | 0.010 |
Why?
| | Drug Synergism | 1 | 2003 | 339 | 0.010 |
Why?
| | Mice, Inbred Strains | 1 | 2003 | 405 | 0.010 |
Why?
| | Programmed Cell Death 1 Ligand 2 Protein | 1 | 2001 | 14 | 0.010 |
Why?
| | CD28 Antigens | 1 | 2001 | 46 | 0.010 |
Why?
| | Dimerization | 1 | 2001 | 183 | 0.010 |
Why?
| | Gene Library | 1 | 2001 | 127 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2001 | 372 | 0.010 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2001 | 190 | 0.010 |
Why?
| | Genetic Vectors | 1 | 2001 | 302 | 0.010 |
Why?
| | Image Cytometry | 1 | 1998 | 3 | 0.010 |
Why?
| | HTLV-I Infections | 1 | 1998 | 21 | 0.010 |
Why?
| | Human T-lymphotropic virus 1 | 1 | 1998 | 23 | 0.010 |
Why?
| | HLA-A2 Antigen | 1 | 1998 | 39 | 0.010 |
Why?
| | Immunity, Active | 1 | 1998 | 10 | 0.010 |
Why?
| | Recombinant Fusion Proteins | 1 | 2001 | 653 | 0.010 |
Why?
| | E2F5 Transcription Factor | 1 | 1997 | 1 | 0.010 |
Why?
| | E2F4 Transcription Factor | 1 | 1997 | 6 | 0.010 |
Why?
| | Immunologic Memory | 1 | 1998 | 313 | 0.010 |
Why?
| | HeLa Cells | 1 | 1997 | 583 | 0.010 |
Why?
| | Proteins | 1 | 2001 | 938 | 0.010 |
Why?
| | Rats | 1 | 2003 | 5392 | 0.010 |
Why?
| | Models, Genetic | 1 | 1997 | 595 | 0.010 |
Why?
| | Genes | 1 | 1994 | 231 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 1994 | 510 | 0.010 |
Why?
| | Molecular Weight | 1 | 1992 | 343 | 0.010 |
Why?
| | Mutagenesis, Site-Directed | 1 | 1992 | 363 | 0.010 |
Why?
| | Transfection | 1 | 1992 | 888 | 0.010 |
Why?
|
|
Slansky's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|